Carregant...
Exceptional response to FOLFIRINOX in a patient with pancreatic cancer and a germline RAD51C mutation
Pancreatic cancer is projected to become the second leading cause of cancer death in the United States by 2030. Deleterious germline mutations can contribute to pancreatic cancer susceptibility. Herein we report a case of a patient with metastatic pancreatic adenocarcinoma to the lung and liver who...
Guardat en:
| Publicat a: | J Gastrointest Oncol |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
AME Publishing Company
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6087861/ https://ncbi.nlm.nih.gov/pubmed/30151275 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jgo.2018.03.11 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|